vs
艾伯维（ABBV）与TENET HEALTHCARE CORP（THC）财务数据对比。点击上方公司名可切换其他公司
艾伯维的季度营收约是TENET HEALTHCARE CORP的3.0倍（$16.6B vs $5.5B）。TENET HEALTHCARE CORP净利率更高（11.7% vs 10.9%，领先0.7%）。艾伯维同比增速更快（10.0% vs 9.0%）。艾伯维自由现金流更多（$4.9B vs $367.0M）。过去两年艾伯维的营收复合增速更高（16.2% vs 1.5%）
艾伯维是一家总部位于美国伊利诺伊州北芝加哥的制药企业，专注于研发、生产覆盖多种疾病领域的治疗药物，致力于为全球各地患者提供安全有效的临床解决方案，在全球医药行业拥有较高的知名度与影响力。
Tenet Healthcare Corporation是总部位于美国达拉斯的营利性跨国医疗服务企业，旗下拥有USPI等多个品牌、子公司、合资企业及合作主体，运营65家医院及超过450个医疗设施，还通过旗下Conifer Health Solutions为各类医疗系统及其他客户提供专业医疗支持服务
ABBV vs THC — 直观对比
营收规模更大
ABBV
是对方的3.0倍
$5.5B
营收增速更快
ABBV
高出1.1%
9.0%
净利率更高
THC
高出0.7%
10.9%
自由现金流更多
ABBV
多$4.5B
$367.0M
两年增速更快
ABBV
近两年复合增速
1.5%
损益表 — Q4 2025 vs Q4 2025
| 指标 | | |
|---|---|---|
| 营收 | $16.6B | $5.5B |
| 净利润 | $1.8B | $644.0M |
| 毛利率 | 72.6% | — |
| 营业利润率 | 27.3% | 15.4% |
| 净利率 | 10.9% | 11.7% |
| 营收同比 | 10.0% | 9.0% |
| 净利润同比 | 8354.5% | 12.6% |
| 每股收益（稀释后） | $1.02 | $4.22 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ABBVTHC
| Q4 25 | $16.6B | $5.5B | ||
| Q3 25 | $15.8B | $5.3B | ||
| Q2 25 | $15.4B | $5.3B | ||
| Q1 25 | $13.3B | $5.2B | ||
| Q4 24 | $15.1B | $5.1B | ||
| Q3 24 | $14.5B | $5.1B | ||
| Q2 24 | $14.5B | $5.1B | ||
| Q1 24 | $12.3B | $5.4B |
净利润ABBVTHC
| Q4 25 | $1.8B | $644.0M | ||
| Q3 25 | $186.0M | $579.0M | ||
| Q2 25 | $938.0M | $522.0M | ||
| Q1 25 | $1.3B | $622.0M | ||
| Q4 24 | $-22.0M | $572.0M | ||
| Q3 24 | $1.6B | $681.0M | ||
| Q2 24 | $1.4B | $477.0M | ||
| Q1 24 | $1.4B | $2.3B |
毛利率ABBVTHC
| Q4 25 | 72.6% | — | ||
| Q3 25 | 66.4% | — | ||
| Q2 25 | 71.8% | — | ||
| Q1 25 | 70.0% | — | ||
| Q4 24 | 70.9% | — | ||
| Q3 24 | 70.9% | — | ||
| Q2 24 | 70.9% | — | ||
| Q1 24 | 66.7% | — |
营业利润率ABBVTHC
| Q4 25 | 27.3% | 15.4% | ||
| Q3 25 | 12.1% | 16.8% | ||
| Q2 25 | 31.7% | 15.6% | ||
| Q1 25 | 28.0% | 18.1% | ||
| Q4 24 | -9.9% | 16.2% | ||
| Q3 24 | 26.5% | 21.3% | ||
| Q2 24 | 27.6% | 14.9% | ||
| Q1 24 | 22.7% | 61.2% |
净利率ABBVTHC
| Q4 25 | 10.9% | 11.7% | ||
| Q3 25 | 1.2% | 10.9% | ||
| Q2 25 | 6.1% | 9.9% | ||
| Q1 25 | 9.6% | 11.9% | ||
| Q4 24 | -0.1% | 11.3% | ||
| Q3 24 | 10.8% | 13.3% | ||
| Q2 24 | 9.5% | 9.3% | ||
| Q1 24 | 11.1% | 43.5% |
每股收益（稀释后）ABBVTHC
| Q4 25 | $1.02 | $4.22 | ||
| Q3 25 | $0.10 | $3.86 | ||
| Q2 25 | $0.52 | $3.14 | ||
| Q1 25 | $0.72 | $4.27 | ||
| Q4 24 | $-0.03 | $3.79 | ||
| Q3 24 | $0.88 | $4.89 | ||
| Q2 24 | $0.77 | $2.64 | ||
| Q1 24 | $0.77 | $21.38 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $5.3B | $2.9B |
| 总债务越低越好 | $58.9B | $13.1B |
| 股东权益账面价值 | $-3.3B | $4.2B |
| 总资产 | $134.0B | $29.7B |
| 负债/权益比越低杠杆越低 | — | 3.10× |
8季度趋势，按日历期对齐
现金及短期投资ABBVTHC
| Q4 25 | $5.3B | $2.9B | ||
| Q3 25 | $5.7B | $3.0B | ||
| Q2 25 | $6.5B | $2.6B | ||
| Q1 25 | $5.2B | $3.0B | ||
| Q4 24 | $5.6B | $3.0B | ||
| Q3 24 | $7.3B | $4.1B | ||
| Q2 24 | $13.2B | $2.9B | ||
| Q1 24 | $18.1B | $2.5B |
总债务ABBVTHC
| Q4 25 | $58.9B | $13.1B | ||
| Q3 25 | $63.0B | $13.1B | ||
| Q2 25 | $63.0B | $13.1B | ||
| Q1 25 | $64.5B | $13.1B | ||
| Q4 24 | $60.3B | $13.1B | ||
| Q3 24 | $58.5B | $12.8B | ||
| Q2 24 | $58.0B | $12.8B | ||
| Q1 24 | $63.8B | $12.8B |
股东权益ABBVTHC
| Q4 25 | $-3.3B | $4.2B | ||
| Q3 25 | $-2.6B | $4.0B | ||
| Q2 25 | $-183.0M | $3.7B | ||
| Q1 25 | $1.4B | $4.2B | ||
| Q4 24 | $3.3B | $4.2B | ||
| Q3 24 | $6.0B | $3.8B | ||
| Q2 24 | $6.8B | $3.5B | ||
| Q1 24 | $8.0B | $3.5B |
总资产ABBVTHC
| Q4 25 | $134.0B | $29.7B | ||
| Q3 25 | $133.9B | $29.4B | ||
| Q2 25 | $137.2B | $28.7B | ||
| Q1 25 | $136.2B | $29.2B | ||
| Q4 24 | $135.2B | $28.9B | ||
| Q3 24 | $143.4B | $29.4B | ||
| Q2 24 | $141.9B | $29.3B | ||
| Q1 24 | $148.9B | $28.9B |
负债/权益比ABBVTHC
| Q4 25 | — | 3.10× | ||
| Q3 25 | — | 3.26× | ||
| Q2 25 | — | 3.49× | ||
| Q1 25 | 45.44× | 3.13× | ||
| Q4 24 | 18.15× | 3.14× | ||
| Q3 24 | 9.70× | 3.33× | ||
| Q2 24 | 8.56× | 3.67× | ||
| Q1 24 | 7.97× | 3.70× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $5.2B | $731.0M |
| 自由现金流经营现金流 - 资本支出 | $4.9B | $367.0M |
| 自由现金流率自由现金流/营收 | 29.4% | 6.6% |
| 资本支出强度资本支出/营收 | 2.0% | 6.6% |
| 现金转化率经营现金流/净利润 | 2.87× | 1.14× |
| 过去12个月自由现金流最近4个季度 | $17.8B | $2.5B |
8季度趋势，按日历期对齐
经营现金流ABBVTHC
| Q4 25 | $5.2B | $731.0M | ||
| Q3 25 | $7.0B | $1.1B | ||
| Q2 25 | $5.2B | $936.0M | ||
| Q1 25 | $1.6B | $815.0M | ||
| Q4 24 | $7.0B | $-331.0M | ||
| Q3 24 | $5.4B | $1.0B | ||
| Q2 24 | $2.3B | $747.0M | ||
| Q1 24 | $4.0B | $586.0M |
自由现金流ABBVTHC
| Q4 25 | $4.9B | $367.0M | ||
| Q3 25 | $6.6B | $778.0M | ||
| Q2 25 | $4.9B | $743.0M | ||
| Q1 25 | $1.4B | $642.0M | ||
| Q4 24 | $6.8B | $-661.0M | ||
| Q3 24 | $5.2B | $829.0M | ||
| Q2 24 | $2.0B | $602.0M | ||
| Q1 24 | $3.8B | $346.0M |
自由现金流率ABBVTHC
| Q4 25 | 29.4% | 6.6% | ||
| Q3 25 | 42.1% | 14.7% | ||
| Q2 25 | 31.7% | 14.1% | ||
| Q1 25 | 10.5% | 12.3% | ||
| Q4 24 | 44.7% | -13.0% | ||
| Q3 24 | 35.9% | 16.2% | ||
| Q2 24 | 14.0% | 11.8% | ||
| Q1 24 | 31.3% | 6.4% |
资本支出强度ABBVTHC
| Q4 25 | 2.0% | 6.6% | ||
| Q3 25 | 2.4% | 5.3% | ||
| Q2 25 | 1.7% | 3.7% | ||
| Q1 25 | 1.8% | 3.3% | ||
| Q4 24 | 1.9% | 6.5% | ||
| Q3 24 | 1.7% | 4.2% | ||
| Q2 24 | 1.7% | 2.8% | ||
| Q1 24 | 1.6% | 4.5% |
现金转化率ABBVTHC
| Q4 25 | 2.87× | 1.14× | ||
| Q3 25 | 37.76× | 1.83× | ||
| Q2 25 | 5.49× | 1.79× | ||
| Q1 25 | 1.27× | 1.31× | ||
| Q4 24 | — | -0.58× | ||
| Q3 24 | 3.49× | 1.53× | ||
| Q2 24 | 1.66× | 1.57× | ||
| Q1 24 | 2.95× | 0.25× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
ABBV
暂无分部数据
THC
| Other | $2.9B | 52% |
| Health Care Patient Service | $1.4B | 25% |
| Equity Method Investment Nonconsolidated Investee Or Group Of Investees | $1.2B | 22% |
| Health Care Other Sources | $56.0M | 1% |
